ORMP, US68403P2039

Barron's lists USD 7.00 target for Oramed Pharmaceuticals stock

Published on 10/20/2026 at 18:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Oramed will report Q3 earnings on November 16, 2026. ORMP stock costs EUR 3.73 on October 20, 2026 at 6:30 p.m. CEST at Lang & Schwarz.

Analyst target and reporting date

Barron's listed a USD 7.00 average target for Oramed Pharmaceuticals on September 22, 2026.
Oramed's next Q3 2026 earnings date is November 16, 2026.
ORMP stock costs EUR 3.73 at Lang & Schwarz on October 20, 2026 at 6:30 p.m. CEST.

ORMP, US68403P2039, Illustration mit AI erstellt.

Oramed Pharmaceuticals (ISIN US68403P2039) has a USD 7.00 average analyst target, while its stock was quoted at EUR 3.73 at Lang & Schwarz on October 20, 2026 at 6:30 p.m. CEST. On September 22, 2026, Barron's listed one rating with an average target of USD 7.00.

The target remains a useful valuation marker because the cited analyst view is materially above the quoted home-market price of USD 4.75 shown on the same September 22 page. The currencies differ from the euro quote, so the two price levels are presented separately rather than combined into an implied return.

Quarterly earnings set for November

Oramed is scheduled to report third-quarter 2026 earnings on November 16, 2026, according to the earnings calendar on the Barron's research page. That date gives investors a defined next checkpoint for the oral-drug developer, whose pipeline includes oral delivery programs for insulin and glucagon-like peptide-1 therapies.

Recent results showed a wide gap

Oramed reported diluted earnings per share of negative USD 0.09 for the quarter reported on August 10, 2026, compared with a consensus estimate of USD 0.43, a shortfall of USD 0.52, MarketBeat reported on October 2, 2026. The comparison puts the November report in a sharper context than the target alone.

Nasdaq valuation remains compact

Oramed's Nasdaq market capitalization was USD 174.3 million on October 20, 2026, with a trailing price-to-earnings ratio of 1.02 and a volume of 92,841 shares. The 52-week range was USD 2.09 to USD 5.47 on September 22, 2026, placing the quoted Nasdaq price of USD 4.75 inside that band.

The company is a biotechnology developer focused on oral delivery solutions for medicines traditionally given by injection. Its reported second-quarter 2026 cash balance was USD 15.2 million as of June 30, 2026, while operating cash flow was negative USD 0.2 million for the quarter.

Price and upcoming dates

The November 16, 2026 earnings date is the next concrete reporting milestone. Barron's also listed March 3, 2027 as the planned fiscal-year 2026 reporting date, giving the market a later checkpoint beyond the third-quarter release.

Oramed stock quote

Oramed Pharmaceuticals was trading at EUR 3.73 at Lang & Schwarz on October 20, 2026 at 6:30 p.m. CEST. The Nasdaq quote was USD 4.75 on September 22, 2026 at 4:00 p.m. EDT.

The further course of trading is shown by the continuously updated real-time quote of Oramed Pharmaceuticals stock.